Safety/Efficacy White Papers & Case Studies
-
KoKo® Spirometry Brochure
4/27/2012
Designed for centralized spirometry KoKo® is the number one choice for respiratory testing in the clinical trial industry.
-
KoKo® DigiDoser Brochure
4/27/2012
Designed for both centralized bronchial challenge and centralized spirometry, the KoKo® DigiDoser spirometer automates timing of challenge stages and dosing intervals, decreasing opportunity for user error, while providing the most advanced, controlled, and reproducible aerosol dosing available. Redefining accuracy in every step of the testing process, nSpire Health’s KoKo DigiDoser delivers the most accurate test results possible.
-
Pharmacovigilance Monitoring Services
1/18/2012
Norwich Clinical Services offers comprehensive pharmacovigilance services for pre-marketing product safety, post-marketing surveillance and data analysis.
-
Epilepsy Drug Study: Ambulatory EEG Application For Safety And Efficacy
1/9/2012
A global leader dedicated to the development and commercialization of pharmaceuticals to treat serious neurological and psychiatric disorders.
-
Adverse Event Reporting, Safety And Compliance Software
12/23/2011
Adverse event (AE) reporting is a key process point for maintaining safety and compliance. Unfortunately, it’s also incredibly labor-intensive.
-
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study For Evaluation Of Efficacy And Safety Of Study Drug Versus Warfarin In Subjects With Atrial Fibrillation
11/23/2011
Atrial fibrillation (AF) is the most common type of arrhythmia in adults and becomes more common with increased age.
-
The Case For The Use Of Point-Of-Care Testing In Pharmaceutical Clinical Trials
11/22/2011
Clinical trials that are designed to evaluate the efficacy of novel pharmaceuticals require a variety of diagnostic tests to be performed on all enrolled patients.
-
White Paper: Understanding the 505(b)(2) Approval Pathway
8/5/2011
Explore how the 505(b)(2) regulatory pathway can help drug developers gain approval for new drugs in a fraction of the time and cost required by traditional paths.